A Phase I Study of LDE225 with Etoposide and Cisplatin for the Initial Treatment of Extensive Small Cell Lung Cancer

Full Title

A Phase I Trial of the Combination of the Hedgehog Inhibitor, LDE-225, with Etoposide and Cisplatin in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Purpose

Etoposide and cisplatin are two chemotherapy drugs commonly used to treat small cell lung cancer (SCLC). However, many patients still succumb to the disease. In this study, researchers want to find the highest dose of an investigational drug called LDE225 that can be given safely with etoposide and cisplatin in patients with extensive SCLC.

LDE225 works by inhibiting a cell signaling pathway called the Hedgehog pathway, which may be important for the growth of SCLC. It is a pill that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have extensive SCLC that has not yet been treated.
  • At least 4 weeks must have passed since any major surgery and entry into the study.
  • Patients must be age 18 or older.

For more information and to inquire about eligibility for this study, please contact Dr. M. Catherine Pietanza at 646-888-4203.

Protocol

11-206

Phase

I

Investigator